-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
-
Summary
-
ZyVersa Therapeutics, Inc. quarterly Goodwill history and growth rate from Q4 2022 to Q2 2023.
- ZyVersa Therapeutics, Inc. Goodwill for the quarter ending June 30, 2023 was $11.9M.